Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma
- 1 January 2006
- journal article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 47 (6), 1103-1109
- https://doi.org/10.1080/10428190600564803
Abstract
In the present phase II study, we tested the efficacy of a single course of rituximab (375 mg/m2 on days 1, 8, 15 and 22) as treatment for relapsed myeloma. The rationale for this study was the identification of a population of clonotypic CD20+ B cells that are believed to be precursors of malignant plasma cells. In addition, CD20 was expressed on 10% and 50% of bone marrow plasma cells in two of the ten patients enrolled. Following rituximab treatment, none of the patients achieved an objective response. Two patients had stable disease at month 6, the predefined end of the study, while, at that time, two patients were classified as having progressive disease. One patient opted to withdraw from the study at month 3, at which time he had stable disease. The other five patients had to be withdrawn early from the post-treatment observation because of need of salvage therapy for progressive disease. WHO grade <or=2 toxicity was seen in four patients. Peripheral B cells significantly decreased at 3 months, while no significant change of bone marrow myeloma cells was noted at that time. Mean paraprotein levels increased slightly during follow-up but IgM levels dropped in all patients, indicating an effective targeting of normal, short-lived plasma cells. Taken together, rituximab treatment yielded significant reductions in circulating B cells and serum IgM levels but had no beneficial clinical effect.Keywords
This publication has 21 references indexed in Scilit:
- Characterization of clonogenic multiple myeloma cellsBlood, 2004
- Short progression‐free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantationBritish Journal of Haematology, 2003
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myelomaBlood, 2003
- Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significanceBritish Journal of Haematology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic ApplicationsJournal of Immunotherapy, 2002
- A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain ReactionBlood, 1998
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995 Jun 1;85(11):3365]Blood, 1995